Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir dose-ranging study with optimized background therapy in treatment-experienced HIV infection
2004-005037-19Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Raltegravir + optimized background therapy with Placebo + optimized background therapy (2 arms). Primary endpoints: Safety and tolerability at Week 24, HIV RNA changes at Week 24 and 3 more. Started Feb 2005; status: terminated.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2004-005037-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005037-19.